CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Influenza vaccine GSK2186877A formulation 1 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01096056
NCT01096056Phase 1Completed
CompareCT.gov

Safety and Immunogenicity of GSK2186877A Candidate Seasonal Influenza Vaccine in Healthy Children 6 to 35 Months of Age.

GlaxoSmithKline·interventional·Posted Mar 30, 2010·Updated Sep 24, 2018

In Brief

A Phase 1 clinical trial evaluating Influenza vaccine GSK2186877A formulation 1, Influenza vaccine GSK2186877A formulation 2, and 1 other intervention for Influenza. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in healthy children 6 to 35 months of age. This Protocol Posting has been updated following Amendment 1 of the Protocol, Jun 2010. The impacted sections are study design, outcome measures, intervention sections and number of subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesSpain
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 30, 2010
Enrollment StartApr 5, 2010
Primary CompletionDec 13, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.3 years ago

Interventions

Influenza vaccine GSK2186877A formulation 1biological

Intramuscular administration, 2 doses

Influenza vaccine GSK2186877A formulation 2biological

Intramuscular administration, 1 dose

Fluarixbiological

Intramuscular administration, 1 dose